OVLH $25.93 -0.6787%
FMC $108.76 -0.6758%
RBB $9.39 -1.6754%
CHM.PA $156.92 0.2216%
MODD $1.41 -6%
CLDT $9.87 -0.303%
VAL $58.76 1.4503%
MGPI $101.02 1.3952%
IPA $3.34 15.564%
1691.HK $7.19 3.9017%
PFHD $28.65 0%
AAMC $81.48 -2.8265%
0KS3.L $292.36 -0.905%
TRNS $84.08 0.8153%
GRC.L $12.36 -8.4444%
CLSD $1.05 -2.7778%
MBIN $22.31 -2.6189%
SK3.IR $34.16 -1.7544%
DFSV $23.24 -0.6838%
XSW $115.16 -1.3888%
PTBD $20.22 -0.4431%
FDIS $64.50 -1.2176%
BNE $24.32 0.584%
3877.HK $1.39 0.7246%
SHLD $31.37 0%
BHGU.L $19.90 0%
0IDU.L $32.61 2.6392%
0VIK.L $4.92 -4.466%
BOCH $15.17 0%
MBLY3.SA $2.29 1.7778%
9074.HK $20.02 -0.1994%
OPCT3.SA $3.40 1.4925%
MLP $12.07 -2.3463%
0767.HK $0.04 0%
6988.HK $0.99 -1%
BCN.L $67.00 0%
ITW $225.90 -0.8798%
LCID $7.00 -0.9207%
MIC $4.09 0%
OSS $2.60 -3.7037%
REVB.L $19.00 0%
0702.HK $0.17 0%
FRC-PN $1.76 0%
UHS.L $35.00 0%
0IUX.L $170.19 -1.5731%
EQTL3.SA $28.89 1.6895%
URNM $31.63 -0.2208%
MIGO.L $324.00 0.6211%
SPIR $0.71 -0.6576%
BSVN $23.00 0.1306%
ITUB $5.42 -0.6422%
FSJ.L $358.00 2.1398%
7272.HK $6.52 0%
MTVC $10.49 0%
IVEG $20.08 0.008%
GPE.PA $44.20 1.6092%
WCLD $26.59 -1.6278%
INSE $13.56 -2.0939%
0OAL.L $51.94 -1.5786%
EFC-PB $18.25 -0.3821%
QCLU.L $18.19 4.227%
0146.HK $0.80 -3.6145%
NGAS.L $0.01 -0.6329%
MTR $21.00 -2.6877%
PSB.PA $30.00 0%
MGAM $0.55 -3.1403%
ENO $24.12 0.4581%
0772.HK $33.05 -2.5074%
RRBI $44.75 -1.165%
CBEE3.SA $13.00 0%
AGRX $5.05 -11.0915%
0P0000KSP7.L $41 389.00 0.2592%
BZH $20.79 -3.9279%
EMHD.PA $21.47 -0.5328%
SPG.NZ $1.29 -1.5267%
1349.HK $3.03 -1.9417%
MRAI $0.68 3.0046%
HYPR $1.42 -0.7063%
VENAR $0.30 0%
SLV $22.03 -0.777%
NSS $25.49 -0.0588%
UC64.L $2 863.50 0.2012%
1753.HK $0.44 -2.2222%
VZIO $7.69 -1.9133%
WPF $9.75 0%
NCZ $2.92 -1.1864%
INVE $6.95 -0.8559%
GDNR $10.69 1.5195%
8305.HK $0.02 0%
7226.HK $4.67 0.1286%
DWAS $72.26 -0.5451%
WBIF $25.97 -0.0112%
SWIS.CN $0.30 0%
2086.HK $0.91 3.4091%
PSCD $86.74 -0.2099%
NYCB-PA $19.91 -0.1004%
ISBC $13.87 0%
ARW.L $307.00 0%
SCC $22.88 -0.0214%
Eng
Логотип
Eng
Лого

Orphazyme A/S 0CUM.L

$0.70

На 12:32, 11 мая 2023

Ключевые показатели

  • Marketcap

    24776544.00000000

  • week52high

    0.00

  • week52low

    0.00

  • Revenue

  • P/E TTM

    0

  • Beta

    0.84847300

  • EPS

    -17.94000000

  • Last Dividend

    0.28500000

  • Next Earnings Date

    07 мая 2023 г. в 03:51

Описание компании

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек